NOVO NORDISK A/S-B (NOV.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:NOV - DK0062498333 - Common Stock
NOV.DE Key Statistics, Chart & Performance
The current stock price of NOV.DE is 44.345 EUR. In the past month the price increased by 4.61%. In the past year, price decreased by -48.13%.
NOV.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 10.85 | 200.34B | ||
| 1SAN.MI | SANOFI | 10.83 | 199.91B | ||
| SAN.PA | SANOFI | 10.83 | 199.95B | ||
| MRK.DE | MERCK KGAA | 14.22 | 52.74B | ||
| UCB.BR | UCB SA | 36.48 | 45.55B | ||
| UNC.DE | UCB SA | 37.27 | 46.55B | ||
| BAYN.DE | BAYER AG-REG | 7.12 | 37.33B | ||
| 1BAYN.MI | BAYER AG-REG | 7.06 | 37.04B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.51 | 10.10B | ||
| IPN.PA | IPSEN | 11.3 | 9.73B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 101.44 | 9.39B | ||
| VIRP.PA | VIRBAC SA | 20.39 | 2.97B |
Related stock screener links
About NOV.DE
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
NOVO NORDISK A/S-B
Novo Alle 1
Bagsvaerd DK
Employees: 78554
Phone: 4544448888
NOVO NORDISK A/S-B / NOV.DE FAQ
What does NOV do?
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Can you provide the latest stock price for NOVO NORDISK A/S-B?
The current stock price of NOV.DE is 44.345 EUR. The price increased by 0.69% in the last trading session.
Does NOV stock pay dividends?
NOVO NORDISK A/S-B (NOV.DE) has a dividend yield of 2.47%. The yearly dividend amount is currently 1.33.
How is the ChartMill rating for NOVO NORDISK A/S-B?
NOV.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Would investing in NOVO NORDISK A/S-B be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NOV.DE.
What is the ownership structure of NOVO NORDISK A/S-B (NOV.DE)?
You can find the ownership structure of NOVO NORDISK A/S-B (NOV.DE) on the Ownership tab.
NOV.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NOV.DE. When comparing the yearly performance of all stocks, NOV.DE is a bad performer in the overall market: 94.83% of all stocks are doing better.
NOV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NOV.DE. NOV.DE scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
NOV.DE Financial Highlights
Over the last trailing twelve months NOV.DE reported a non-GAAP Earnings per Share(EPS) of 3.12. The EPS increased by 10.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.88% | ||
| ROA | 20.26% | ||
| ROE | 61.08% | ||
| Debt/Equity | 0.52 |
NOV.DE Forecast & Estimates
32 analysts have analysed NOV.DE and the average price target is 54.95 EUR. This implies a price increase of 23.92% is expected in the next year compared to the current price of 44.345.
For the next year, analysts expect an EPS growth of 4.79% and a revenue growth 7.98% for NOV.DE